LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)
LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data
LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry Age-Related Macular Degeneration
LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects